ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Infectious disease

Lilly will test baricitinib against COVID-19

by Michael McCoy
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

09815-buscon17-bari.jpg

Eli Lilly and Company and the US National Institute of Allergy and Infectious Diseases will study baricitinib, a Lilly rheumatoid arthritis drug, as a potential treatment for people with COVID-19. It’s thought that baricitinib’s anti-inflammatory effect could help reduce the cytokine storm that COVID-19 can trigger in patients. Ruxolitinib, a cancer treatment from Novartis and Incyte, is also being tested for its potential to dampen the cytokine storm.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

CORRECTION

This story was updated on April 20, 2020, to correctly state the partners that market ruxolitinib. They are Novartis and Incyte, not Novartis and Regeneron.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment